Emergent BioSolutions (EBS) PT Raised to $130 at Cantor Fitzgerald Following EPS
- Shares jump on tech boost; fragile yen on intervention watch
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Oil prices climb amid US stocks decline, Middle East conflict
- Yen on the brink, but Tesla pulls back
- Dollar recovers from PMI slump, yen closes in on 155 per dollar
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Emergent BioSolutions (EBS) Tops Q4 EPS by 48c, Revenues Beat; Offers FY21 Revenue Guidance Above Consensus
February 18, 2021 4:20 PM ESTEmergent BioSolutions (NYSE: EBS) reported Q4 EPS of $3.67, $0.48 better than the analyst estimate of $3.19. Revenue for the quarter came in at $583 million versus the consensus estimate of $563.94 million.
Emergents financial and operational performance in 2020 reflects the impact we are making in addressing the... More